Issues

CRISPR-based ecDNA induction reveals the role of both NHEJ and MMEJ in ecDNA formation and demonstrates that ecDNA and corresponding chromosomal deletions form at distinct rates and respond differently to pharmacologic modulation.

This study describes an exceptional, alternative pathway of SCLC pathogenesis via chromothripsis and ecDNA in the absence of RB1 and TP53 mutations or smoking mutagenesis, defining a novel tumor type associated with distinct prognosis and therapeutic profile.

A genome-wide machine learning approach integrating cfDNA fragmentomes and biomarkers detected all stages of ovarian cancer with high sensitivity and specificity, and may enable new, accessible screening modalities.

Zongertinib, a covalent HER2 inhibitor, is active in HER2-driven preclinical models and patients and effectively targets HER2 oncogenic signaling while sparing wild-type EGFR, resulting in potent inhibition and improved tolerability.

Treatment with AMG 193 preferentially inhibits the growth of MTAP-deleted tumors in preclinical models and demonstrates clinical activity in ongoing early phase trials.

KRAS inhibition synergizes with an immunotherapy comprising of a CXCR1/2 inhibitor, an antagonistic anti-LAG3, and an agonistic anti-41BB to elicit durable, complete regressions of autochthonous tumors in the iKPC PDAC model.

Genetic and pharmacologic approaches uncover functionally relevant microenvironment heterogeneity to improve the efficacy of immunotherapy in brain metastasis.

In colorectal cancer, NGF is upregulated in cancer-associated fibroblasts (CAFs) via the β2-adrenergic receptor, and the bidirectional interplay between NGF⁺ CAFs and adrenergic nerves drives tumor progression.

Analysis of 16,049 animal necropsies from 292 vertebrate species shows that cancer prevalence increases with body mass and somatic mutation rates, but decreases with gestation time.